… efficacy than gefitinib or erlotinib in first-line treatment of EGFR-… effective than erlotinib as
second-line treatment of patients with … studies, with emphasis on comparability between gefitinib …

… study showed that erlotinib and gefitinib had similar effectiveness but gefitinib had a better
safety profile compared to erlotinib… erlotinib and gefitinib for treating NSCLC in our study …

… Treatment schedule … at a 1 : 1 ratio to receive oral erlotinib 150 mg or gefitinib 250 mg once
daily. Second- and further-line treatments were defined as second line in the present study. …

… entry, because we recognized that a significant proportion of patients included in this
study did not have EGFR activating mutation and may have had a shorter duration of …

… The EGFR-TKIs investigated in this study were gefitinib and erlotinib. Afatinib had not yet
been approved by NHI during the study period. The prescription duration of individual EGFR-…

… This study was the first to directly compare EGFR-TKIs treatment efficacy in … erlotinib- and
gefitinib-treated groups (11.7 vs. 14.5 months; P=0.507) in a retrospective case-control study of …

… -line therapy is still a controversial issue. The aim of this study was to compare the effectiveness
of gefitinib, erlotinib, and … NSCLC including 147 patients treated with EGFR TKIs. Time to …

… therapy for EGFR-mutant NSCLC was first reimbursed in Korea (October 2014). Our purpose
of this study is to … it leads to different clinical outcomes compared with gefitinib or erlotinib. …

… study, the primary objective was to determine the pooled overall treatment effect on OS of
firstline therapy with gefitinib … this meta-analysis of gefitinib and erlotinib as most of the included …

… , but patients with exon 20 point mutations from another phase I study (NCT02113813)
without available standard-of-care therapies could continue ASP8273 under revised consent …